Your session is about to expire
← Back to Search
Partial Opioid Agonist
Extended-Release Naltrexone + Buprenorphine for Cocaine Use Disorder (CURB-2 Trial)
Phase 2
Recruiting
Led By Madhukar Trivedi, MD
Research Sponsored by University of Texas Southwestern Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be 18 to 65 years of age
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 5 up to week 8
Awards & highlights
Summary
This trial tests if XR-NTX & XR-BUP could reduce cocaine use in people with CUD, compared to a placebo.
Who is the study for?
Adults aged 18-65 with moderate to severe Cocaine Use Disorder, who want to reduce or stop cocaine use. They must have used cocaine frequently in the past month and not be using opioids. Women should agree to birth control measures. People with certain psychiatric conditions, heart issues, liver problems, blood disorders, or those at risk for serotonin syndrome are excluded.Check my eligibility
What is being tested?
The trial is testing if a combination of extended-release naltrexone (XR-NTX) and extended-release buprenorphine (XR-BUP) is more effective than placebo injections in treating Cocaine Use Disorder over an 8-week period. Participants will be randomly assigned to receive either the medication combo or placebo.See study design
What are the potential side effects?
Possible side effects include nausea, headache, dizziness, fatigue, injection site reactions like pain or swelling; mood changes such as anxiety or depression; sleep disturbances; appetite changes; and potential opioid withdrawal symptoms.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am between 18 and 65 years old.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ week 5 up to week 8
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 5 up to week 8
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Proportion of Cocaine-negative UDS
Secondary outcome measures
Mean self reported cocaine craving score
Mean self reported overall functioning
Measures of safety (adverse events)
+1 moreTrial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Drug intervention (XR-NTX+XR-BUP)Experimental Treatment2 Interventions
The study intervention is three doses of 380mg XR-NTX (Weeks 0, 3 and 6) and two doses of 300mg XR-BUP (Weeks 0, 4).
Drug: XR-NTX XR-NTX: 3 intramuscular injections administered Week 0, 3, 6. Other Names: Extended Release Injectable Naltrexone Arm: Experimental
Drug: XR-BUP XR-BUP: 2 subcutaneous injections administered Week 0, 4. Other Names: Extended Release Injectable Buprenorphine Arm: Experimental
Group II: PlaceboPlacebo Group2 Interventions
Matched placebo injections (PBO-Inj) for the treatment of cocaine use disorder (CUD).
Drug: Placebo (PLB) Injectable Placebo: 3 intramuscular injections administered Week 0, 3, 6. Other Names: Injectable matching (to XR-NTX) placebo Arm: Placebo Comparator - matched Placebo (PLB)
Drug: Placebo (PLB) Injectable Placebo: 2 subcutaneous injections administered Week 0, 4. Other Names: Injectable matching (to XR-BUP) placebo Arm: Placebo Comparator - matched Placebo (PLB)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Extended-Release Naltrexone
2014
Completed Phase 4
~990
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Cocaine Use Disorder (CUD) include medications like Extended-Release Naltrexone (XR-NTX) and Extended-Release Buprenorphine (XR-BUP). Naltrexone works as an opioid receptor antagonist, blocking the euphoric and reinforcing effects of opioids, which helps reduce cravings and prevent relapse.
Buprenorphine, a partial opioid agonist, activates opioid receptors to a lesser degree, providing a ceiling effect that minimizes the risk of misuse and dependency. These mechanisms are important for CUD patients as they help manage cravings and reduce the likelihood of relapse, supporting long-term recovery.
A systematic review and meta-analysis of medications for stimulant use disorders in patients with co-occurring opioid use disorders.Co-occurring amphetamine use and associated medical and psychiatric comorbidity among opioid-dependent adults: results from the Clinical Trials Network.
A systematic review and meta-analysis of medications for stimulant use disorders in patients with co-occurring opioid use disorders.Co-occurring amphetamine use and associated medical and psychiatric comorbidity among opioid-dependent adults: results from the Clinical Trials Network.
Find a Location
Who is running the clinical trial?
University of Texas Southwestern Medical CenterLead Sponsor
1,058 Previous Clinical Trials
1,054,697 Total Patients Enrolled
National Institute on Drug Abuse (NIDA)NIH
2,503 Previous Clinical Trials
2,625,157 Total Patients Enrolled
Madhukar Trivedi, MDPrincipal InvestigatorUT Southwestern Medical Center
14 Previous Clinical Trials
10,650 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I agree to use birth control and undergo pregnancy tests if I can conceive.I have not used opioids in the last week and can provide a clean urine sample.I am between 18 and 65 years old.
Research Study Groups:
This trial has the following groups:- Group 1: Drug intervention (XR-NTX+XR-BUP)
- Group 2: Placebo
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger